Broken String Biosciences today announced that it has closed a $15 million Series A investment round.
Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The EMBARK Phase